[go: up one dir, main page]

MX2016006558A - Sistesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexi l]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo. - Google Patents

Sistesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexi l]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.

Info

Publication number
MX2016006558A
MX2016006558A MX2016006558A MX2016006558A MX2016006558A MX 2016006558 A MX2016006558 A MX 2016006558A MX 2016006558 A MX2016006558 A MX 2016006558A MX 2016006558 A MX2016006558 A MX 2016006558A MX 2016006558 A MX2016006558 A MX 2016006558A
Authority
MX
Mexico
Prior art keywords
yloxy
pyridin
benzo
dihydro
tetraaza
Prior art date
Application number
MX2016006558A
Other languages
English (en)
Other versions
MX372971B (es
Inventor
Schwitter Urs
Trussardi René
Grassmann Olaf
Pfleger Christophe
Hartung Thomas
Rothenhäusler Benno
Hoffmann-Emery Fabienne
Michel Adam Jean-
Ran Frederic
Diodone Ralph
Bartels Björn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006558A publication Critical patent/MX2016006558A/es
Publication of MX372971B publication Critical patent/MX372971B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona procesos para preparar 1-[4-(piridin-2-iloxi)-ciclohexil]-5, 6-dihidro-4H-2,3,5,10b-tetra aza-benzo[E]azulenos sustituidos. Se describen además compuestos que resultan útiles como intermediarios en los métodos de la invención.
MX2016006558A 2013-12-05 2014-12-01 Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo. MX372971B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195864 2013-12-05
PCT/EP2014/076041 WO2015082370A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Publications (2)

Publication Number Publication Date
MX2016006558A true MX2016006558A (es) 2016-08-03
MX372971B MX372971B (es) 2020-03-27

Family

ID=49726573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006558A MX372971B (es) 2013-12-05 2014-12-01 Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.

Country Status (19)

Country Link
US (3) US10246460B2 (es)
EP (1) EP3077396B1 (es)
JP (1) JP6454707B2 (es)
KR (3) KR102384608B1 (es)
CN (1) CN105793263B (es)
AR (1) AR098592A1 (es)
AU (2) AU2014359409A1 (es)
CA (2) CA2931016C (es)
ES (1) ES2875411T3 (es)
HR (1) HRP20210966T1 (es)
IL (2) IL245450A0 (es)
MX (1) MX372971B (es)
MY (1) MY175464A (es)
NZ (1) NZ720340A (es)
PL (1) PL3077396T3 (es)
SG (1) SG11201604502SA (es)
SI (1) SI3077396T1 (es)
WO (1) WO2015082370A1 (es)
ZA (1) ZA201603304B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175464A (en) * 2013-12-05 2020-06-29 Hoffmann La Roche Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
PL3720424T3 (pl) 2017-12-08 2022-12-27 F. Hoffmann-La Roche Ag Preparat farmaceutyczny
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
EP4287361A4 (en) 2021-10-06 2025-01-01 LG Energy Solution, Ltd. Battery module

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
SI1597260T1 (sl) * 2003-02-19 2007-04-30 Pfizer Spojine triazola, uporabne pri terapiji
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
PE20110590A1 (es) * 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
MY150837A (en) * 2008-11-28 2014-02-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
CN105492010B (zh) 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
MY175464A (en) 2013-12-05 2020-06-29 Hoffmann La Roche Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Also Published As

Publication number Publication date
MX372971B (es) 2020-03-27
KR20160093709A (ko) 2016-08-08
AU2019201183A1 (en) 2019-03-14
AR098592A1 (es) 2016-06-01
CA2931016A1 (en) 2015-06-11
IL264891B (en) 2021-02-28
US11040977B2 (en) 2021-06-22
JP2016539168A (ja) 2016-12-15
US20190194210A1 (en) 2019-06-27
KR102384630B1 (ko) 2022-04-11
KR20210132745A (ko) 2021-11-04
US20160280712A1 (en) 2016-09-29
KR102384608B1 (ko) 2022-04-08
HK1223918A1 (zh) 2017-08-11
WO2015082370A1 (en) 2015-06-11
AU2014359409A1 (en) 2016-05-19
US10246460B2 (en) 2019-04-02
US20210284648A1 (en) 2021-09-16
SG11201604502SA (en) 2016-07-28
KR102384629B1 (ko) 2022-04-11
CA3142754C (en) 2024-01-02
ZA201603304B (en) 2022-05-25
CN105793263B (zh) 2019-08-23
EP3077396A1 (en) 2016-10-12
AU2019201183B2 (en) 2021-03-04
CN105793263A (zh) 2016-07-20
HRP20210966T1 (hr) 2021-09-17
RU2018135601A (ru) 2018-11-22
KR20210134985A (ko) 2021-11-11
IL245450A0 (en) 2016-06-30
EP3077396B1 (en) 2021-04-21
NZ759478A (en) 2021-06-25
NZ720340A (en) 2020-03-27
RU2018135601A3 (es) 2022-05-05
MY175464A (en) 2020-06-29
CA3142754A1 (en) 2015-06-11
CA2931016C (en) 2022-11-01
JP6454707B2 (ja) 2019-01-16
ES2875411T3 (es) 2021-11-10
SI3077396T1 (sl) 2021-08-31
PL3077396T3 (pl) 2021-10-04
US12459947B2 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2015002516A1 (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
ECSP14020478A (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
MX387128B (es) Métodos para la síntesis de esfingomielinas y dihidroesfingomielinas.
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
BR112014031787A2 (pt) composição, métodos de substituição e para produção de refrigeração e equipamento de refrigeração.
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
UY34018A (es) Derivados glucósidos y usos de los mismos
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2017008097A (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
IN2013MU00848A (es)
MX2016006558A (es) Sistesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexi l]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.
UY34023A (es) Derivados de fenil-isoxazol y procedimiento para la preparación de los mismos

Legal Events

Date Code Title Description
FG Grant or registration